Anavex Life Sciences (AVXL) Reports Q3 Loss of $0.06/Share; No Longer Under SEC Investigation

Anavex Life Sciences (NASDAQ: AVXL) reported Q3 EPS of ($0.06), versus ($0.22) reported last year.

The SEC staff recently advised Company’s legal counsel that the staff did not intend to recommend enforcement action by the Commission against the Company in connection with the investigation previously described in the Company’s 2015 Report on Form 10-K.

For earnings history and earnings-related data on Anavex Life Sciences (AVXL) click here.

You May Also Be Interested In

• Pembina joins proposed 1M bbl/day Alberta-to-coast pipeline plan
• IES Holdings (IESC) files mixed shelf
• Osprey Acquisition Corp. III raises $300M in Nasdaq IPO